Expression of DOG1, PDGFRA, and p16 in Gastrointestinal Stromal Tumors
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The diagnosis of gastrointestinal stromal tumors (GIST) relies on the demonstration of KIT expression,but KIT expression is absent or reduced in approximately 15% of GIST. Methods: Eighty-one GISTs were diagnosed between January 1998 and December 2007 at the Department of Pathology at both Chungnam National University Hospital and Eulji University Hospital, Daejeon. Medical history,patient follow-up, and radiographic data were collected if available in the medical records. To determine diagnostic and prognostic markers for GISTs focused on PDGFRA mutation and clinicopathologic features, we analyzed 81 GIST cases for KIT, PDGFRA, DOG1, and p16 expression and for mutation of PDGFRA genes. Results: Among 81 GIST cases,20 high risk cases (24.7%) were recurred or metastasized. Immunohistochemically, KIT was positive in 76 (93.8%),PDGFRA in 75 (92.7%), and DOG1 in 77 (95.1%). With a cutoff value of 50%, p16 expression was positive in 26 cases were positive (32.1%). A correlation between p16 expression or negative DOG1 expression and recurrence or metastasis was demonstrated (p<0.05). Four cases showed a missense mutation in exon 12 of PDGFRA gene, three of these were of epithelioid GISTs. Two cases showed a silent mutation in exon 18 of PDGFRA. Conclusions: These results indicate that the expression of DOG1 and PDGFRA is observed in a majority of GIST cases. Expression of p16 and negative DOG1expression is predictive for development of recurrence and/or metastasis. Even though mutation of the PDGFRA gene is frequently seen in epithelioid GISTs, a clinicopathologic correlation was not demonstrated.
Abstract
Background/Aims: The diagnosis of gastrointestinal stromal tumors (GIST) relies on the demonstration of KIT expression,but KIT expression is absent or reduced in approximately 15% of GIST. Methods: Eighty-one GISTs were diagnosed between January 1998 and December 2007 at the Department of Pathology at both Chungnam National University Hospital and Eulji University Hospital, Daejeon. Medical history,patient follow-up, and radiographic data were collected if available in the medical records. To determine diagnostic and prognostic markers for GISTs focused on PDGFRA mutation and clinicopathologic features, we analyzed 81 GIST cases for KIT, PDGFRA, DOG1, and p16 expression and for mutation of PDGFRA genes. Results: Among 81 GIST cases,20 high risk cases (24.7%) were recurred or metastasized. Immunohistochemically, KIT was positive in 76 (93.8%),PDGFRA in 75 (92.7%), and DOG1 in 77 (95.1%). With a cutoff value of 50%, p16 expression was positive in 26 cases were positive (32.1%). A correlation between p16 expression or negative DOG1 expression and recurrence or metastasis was demonstrated (p<0.05). Four cases showed a missense mutation in exon 12 of PDGFRA gene, three of these were of epithelioid GISTs. Two cases showed a silent mutation in exon 18 of PDGFRA. Conclusions: These results indicate that the expression of DOG1 and PDGFRA is observed in a majority of GIST cases. Expression of p16 and negative DOG1expression is predictive for development of recurrence and/or metastasis. Even though mutation of the PDGFRA gene is frequently seen in epithelioid GISTs, a clinicopathologic correlation was not demonstrated.
참고문헌 (30)
- Hirota S, "Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors", Science, 279, pp.577~580 (1998)
- Kindblom LG, "Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal", Am J Pathol, 152, pp.1259~1269 (1998)
- Miettinen M, "Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT).", Mod Pathol, 13, pp.1134~1142 (2000)
- Corless CL, "Biology of gastrointestinal stromal tumors", J Clin Oncol, 22, pp.3813~3825 (2004)
- Debiec-Rychter M, "Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity", J Pathol, 202, pp.430~438 (2004)
- Heinrich MC, "PDGFRA activating mutations in gastrointestinal stromal tumors", Science, 299, pp.708~710 (2003)
- Fletcher CD, "Diagnosis of gastrointestinal stromal tumors: a consensus approach", Hum Pathol, 33, pp.459~465 (2002)
- West RB, "The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status", Am J Pathol, 165, pp.107~113 (2004)
- Espinosa I, "A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors", Am J Surg Pathol, 32, pp.210~218 (2008)
- Schneider-Stock R, "High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors", J Clin Oncol, 21, pp.1688~1697 (2003)
- Steigen SE, "Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway", Mod Pathol, 21, pp.46~53 (2008)
- Sabah M, "Loss of heterozygosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumors", Mod Pathol, 17, pp.1364~1371 (2004)
- Schneider-Stock R, "Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study", Clin Cancer Res, 11(2 Pt 1), pp.638~645 (2005)
- Schmieder M, "p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome", Neoplasia, 10, pp.1154~1162 (2008)
- 최송이, "KIT", PDGFRA Expression and Mutation in Testicular Seminoma and Ovarian Dysgerminoma, 2009, pp.43(6), 528~534[DOI]
- Antonescu CR, "Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas", Mod Pathol, 21(Suppl 2), pp.S31~S36 (2008)
- Zheng S, "Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor", Hepatogastroenterology, 54, pp.2285~2290 (2007)
- Miselli F, "PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors", Am J Surg Pathol, 32, pp.738~743 (2008)
- Liegl B, "Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes", Am J Surg Pathol, 33, pp.437~446 (2009)
- Katoh M, "FLJ10261 gene, located within the CCND1- EMS1 locus on human chromosome 11q13, encodes the eighttransmembrane protein homologous to C12orf3, C11orf25 and FLJ34272 gene products", Int J Oncol, 22, pp.1375~1381 (2003)
- Haller F, "Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors", Clin Cancer Res, 11, pp.6589~6597 (2005)
- Agaram NP, "Comparative ultrastructural analysis and KIT", PDGFRA genotype in 125 gastrointestinal stromal tumors, 2006, pp.30, 443~452
- Braconi C, "KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study", Ann Oncol, 19, pp.706~710 (2008)
- Miettinen M, "Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up", Am J Surg Pathol, 30, pp.477~489 (2006)
- Corless CL, "PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib", J Clin Oncol, 23, pp.5357~5364 (2005)
- Miettinen M, "Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up", Am J Surg Pathol, 29, pp.52~68 (2005)
- Lasota J, "A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential", Lab Invest, 84, pp.874~883 (2004)
- Wardelmann E, "Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors", J Mol Diagn, 6, pp.197~204 (2004)
- Chang HM, "PDGFRalpha gene mutation and protein expression in gastrointestinal stromal tumors", Oncology, 74, pp.88~95 (2008)
- Kang HJ, "Correlation of KIT and platelet-derived growth factor receptor α mutations with gene activation and expression profiles in gastrointestinal stromal tumors", ONCOGENE, 24, pp.1066~1074, NATURE PUBLISHING GROUP